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Abstract
Background: Chronic subdural haematoma (CSDH) is a common neurological disease with a rapidly rising incidence due
to increasing age and widespread use of anticoagulants. Surgical intervention by burr-hole craniotomy (BHC) is the current
standard practice for symptomatic patients, but associated with complications, a recurrence rate of up to 30% and increased
mortality. Dexamethasone (DXM) therapy is, therefore, used as a non-surgical alternative but considered to achieve a lower
success rate. Furthermore, the benefit of DXM therapy appears much more deliberate than the immediate relief from BHC.
Lack of evidence and clinical equipoise among caregivers prompts the need for a head-to-head randomised controlled trial.
The objective of this study is to compare the effect of primary DXM therapy versus primary BHC on functional outcome and
cost-effectiveness in symptomatic patients with CSDH.
Methods/Design: This study is a prospective, multicentre, randomised controlled trial (RCT). Consecutive patients with a
CSDH with a Markwalder Grading Scale (MGS) grade 1 to 3 will be randomised to treatment with DXM or BHC. The DXM
treatment scheme will be 16 mg DXM per day (8 mg twice daily, days 1 to 4) which is then halved every 3 days until a
dosage of 0.5 mg a day on day 19 and stopped on day 20. If the treatment response is insufficient (i.e. persistent or
progressive symptomatology due to insufficient haematoma resolution), additional surgery can be performed. The
primary outcomes are the functional outcome by means of the modified Rankin Scale (mRS) score at 3 months and
cost-effectiveness at 12 months. Secondary outcomes are quality of life at 3 and 12 months using the Short Form Health
Survey (SF-36) and Quality of Life after Brain Injury Overall Scale (QOLIBRI), haematoma thickness after 2 weeks on
follow–up computed tomography (CT), haematoma recurrence during the first 12 months, complications and drug-
related adverse events, failure of therapy within 12 months after randomisation and requiring intervention, mortality
during the first 3 and 12 months, duration of hospital stay and overall healthcare and productivity costs. To test non-
inferiority of DXM therapy compared to BHC, 210 patients in each treatment arm are required (assumed adjusted
common odds ratio DXM compared to BHC 1.15, limit for inferiority < 0.9). The aim is to include a total of 420 patients in
3 years with an enrolment rate of 60%.
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Discussion: The present study should demonstrate whether treatment with DXM is as effective as BHC on functional
outcome, at lower costs.
Trial registration: EUCTR 2015-001563-39. Date of registration: 29 March 2015.
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Background
A chronic subdural haematoma (CSDH) is a common
neurological disease with a rapidly rising prevalence due to
increasing age and the widespread use of anticoagulants
[1–4]. It generally affects the elderly population and
patients with coagulopathy, who often have co-existing
medical diseases [1, 5]. The estimated incidence in Western
countries is 8.1 per 100,000 per year in patients aged 65
years or older [6], but increases to 58/100,000/year for
those aged 70 years or older [1, 7].
Surgical intervention by burr-hole craniotomy (BHC)
followed by subdural drainage is the mainstay treat-
ment in symptomatic patients with a CSDH [8, 9],
which leads to a favourable functional outcome in 84%
of patients [10]. However, despite the optimisation of
techniques surgery is still associated with relevant com-
plications, recurrence rates up to 30%, and considerable
mortality [8–12]. In addition, especially advanced age
and the presence of comorbidities could render patients
ineligible for BHC.
Dexamethasone (DXM) therapy has been proposed as an
alternative, non-operative or adjuvant treatment modality
and might have the potential to block the anti-inflammatory
changes in the formation of the haematoma and can speci-
fically impede the formation of neo-membranes and
neo-capillaries by its powerful inhibition of inflammatory
mediators [13, 14]. Therefore, DXM is administered
routinely in various institutions.
To date, only three retrospective and one prospect-
ive study have compared the clinical effect of DXM
to BHC in CSDH patients [15]. To date, no rando-
mised trials have been published that compare both
treatments. Therefore, we designed the DECSA trial:
a randomised controlled, multicentre trial to evaluate
the non-inferiority of primary DXM compared to primary
BHC on functional outcome and cost-effectiveness in
patients with symptomatic CSDH.
Methods/Design
Trial design
This is a prospective, multicentre, open-label, randomised
controlled trial (RCT) with a blinded endpoint (PROBE
design) assessment [16]. Eligible patients are randomised
to DXM therapy (the intervention arm) or BHC (control
arm; see Additional file 1 for SPIRIT check-list).
Primary study objective
The primary objective is to evaluate the non-inferiority
of primary DXM therapy versus primary BHC on func-
tional outcome as expressed by modified Rankin Scale
(mRS) score (Table 1) at 3 months and cost-effectiveness
at 12 months in patients with symptomatic CSDH.
Secondary objectives
The secondary objectives of the study are functional and
clinical outcome, expressed by mRS and Markwalder
Grading Scale (MGS) scores (Table 2), respectively, at
discharge, at 2 weeks, 3, 6 and 12 months and Glasgow
Outcome Scale-Extended (GOSE) score (Table 3) at 3
months. Furthermore, assessment of quality of life using
the Short Form – 36 Health Survey (SF-36) and Quality
of Life after Brain Injury Overall Scale (QOLIBRI) will
take place at 3 and 12 months and healthcare and prod-
uctivity costs at 3 and 12 months. Haematoma thickness
will be evaluated after 2 weeks on follow-up computed
tomography (CT). Mortality will be evaluated during the
first 3 and 12 months. During the total follow-up period
of 12 months we will also evaluate haematoma recur-
rence, complications and drug-related adverse events,
failure of therapy after randomisation and requiring
intervention, duration of hospital stay and overall
healthcare and productivity costs.
Study setting and participants
Patients will be recruited for the study from the emergency
department, neurological or neurosurgical outpatient clinic
or ward or through referral from general hospitals of the
seven participating Dutch neurosurgical hospitals. The
seven participating neurosurgical hospitals are Haaglanden
Medical Centre (HMC) The Hague, Haga Teaching Hos-
pital The Hague, Leiden University Medical Centre
(LUMC) in Leiden, Medisch Spectrum Twente (MST) En-
schede, Erasmus Medical Centre (EMC) Rotterdam, Isala
Hospital Zwolle and University Medical Centre Groningen
(UMCG). The study is open to additional participating
neurosurgical centres.
Inclusion criteria
Eligible patients must be 18 years or older and meet all
of the following criteria:
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1) The presence of a newly diagnosed CSDH, defined
as an isodense or hypodense haematoma in the
subdural space on cranial computed tomography
(CT) scan. Hyperdense components may be present
but must compromise less than one third of the
haematoma
2) Clinical symptoms must be explained by the CSDH
3) The patient is eligible for BHC and DXM based on
clinical symptoms and radiological appearance of
CSDH
4) MGS grade 1–3.
The MGS is a validated grading system (score 0–4, see
Table 2) for the severity of neurological symptoms and is




1) MGS grade 0 or 4
2) An acute subdural haematoma
3) The presence of a minimal CSDH on cranial CT
which is technically not drainable by BHC
4) Pregnancy
5) Cerebrospinal fluid shunt in situ (e.g.
ventriculoperitoneal shunt)
6) Known hypersensitivity to DXM
7) Known ulceration in the gastro-intestinal tract
8) Poorly regulated diabetes mellitus (DM) defined as
a glycosylated haemoglobin (HbA1C) value > 8%
(64 mmol/mol)
9) Clinical suspicion of an acute systemic infection
(fever, leucocytosis, elevated C-reactive protein)
10) History of gastro-intestinal bleeding
11) Glaucoma
12) Previous history of severe affective disorders (i.e.
psychosis).
Participant timeline
The time schedule in Fig. 1 describes all study processes,
assessments and interventions. The flow diagram (Fig. 2)
displays the main study procedures, including follow-up
evaluations.
In summary, study patients will be evaluated at presen-
tation (baseline), during their hospital stay, at discharge
and during the follow-up period at 2 weeks, 3 months, 6
months and 12 months.
At 2 weeks (after initiation of the study treatment) pa-
tients will be evaluated by neurological examination
combined with a follow-up CT scan at the outpatient
clinic or ward and at 3 months at the outpatient clinic.
A mRS-certified research nurse, blinded for treatment
allocation, will evaluate the primary outcome (mRS
score) at 3 months by phone. At 3 and 12 months,
patients will receive questionnaires on quality of life.
Additionally, an evaluation of mRS score will take place
by phone at 3, 6 and 12 months. Healthcare and
productivity costs will be evaluated at 3 and 12 months.
We expect to complete patient inclusion in 3 years. The
estimated duration of the study (including follow-up)
will be 4 years.
Table 1 Modified Rankin Scale (mRS)
Score Functional status
0 No symptoms
1 No significant disability. Able to carry out
all usual activities despite some symptoms
2 Slight disability. Able to look after own
affairs without assistance, but unable to
carry out all previous activities
3 Moderate disability. Requires some help,
but able to walk unassisted
4 Moderately severe disability. Unable to
attend to own bodily needs without
assistance, and unable to walk unassisted
5 Severe disability. Requires constant nursing
care and attention, bedridden, incontinent
6 Dead
Table 2 Markwalder Grading Scale
Score Clinical status
0 Patient neurological normal
1 Patient alert and oriented; mild symptoms such as headache;
absent or mild neurological deficit such as reflex asymmetry
2 Patient drowsy (defined as Glasgow Coma Scale (GCS) score:
13–14) or disoriented with variable neurological deficit, such
as hemiparesis
3 Patient stuporous (defined as GCS 9–12) but responding
appropriately to noxious stimuli; severe focal signs such
as hemiplegia
4 Patient comatose (GCS 8 or lower) with absent motor
responses to painful stimuli; decerebrate or decorticate posturing




3 Severe disability, lower
4 Severe disability, upper
5 Moderate disability, lower
6 Moderate disability, upper
7 Good recovery, lower
8 Good recovery, upper
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Interventions
Investigational treatment
Patients in the intervention arm will receive DXM in a
daily dosage of 16 mg (8 mg every 12 h) on days 1 to 4.
Thereafter, DXM will be tapered by half every 3 days
(see Table 4 for the DXM dosing scheme) until a dosage
of 0.5 mg a day on day 19 and stopped on day 20. DXM
is administered orally in tablets or intravenously when
oral administration is not possible. If the patient im-
proves on DXM therapy (defined by ≥ 1 point decrease
in MGS score) during the first 2 weeks, the treatment
will be continued until day 19. During DXM treatment a
proton pump inhibitor (pantoprazole, 40 mg daily) is
administered as prophylaxis.
DXM therapy can be discontinued for the following
reasons: (1) no improvement of the clinical condition,
defined as an unchanged MGS score 2 weeks after initi-
ation of DXM therapy with unchanged or increased
haematoma on the follow-up CT at 2 weeks, (2) clinical
deterioration, defined by as ≥ 1 point increase in MGS
score, at any time after initiation of DXM treatment, (3)
the occurrence of severe, relevant DXM-related side ef-
fects or complications (i.e. uncontrollable hyperglycaemia,
gastro-intestinal bleeding or psychiatric symptoms), (4)
pre-study complement discontinuation of DXM therapy is
primarily left to the discretion of the treating physician
and is recommended in case of: persistence of moderate
to severe neurological symptoms (MGS grade 2–3) in
combination with the presence of relevant severe, current
comorbidities (i.e. an infection, metabolic deterioration)
which could interfere with the expected recovery, and a
surgical intervention could be beneficial and the safest
option for patient recovery.
In any case of pre-study discontinuation of DXM
therapy, the reason for this is documented. Whenever
DXM is discontinued, a cross-over to the reference
treatment (BHC) can occur depending on the remaining
symptoms, which is the local standard of care in the par-
ticipating hospitals.
Reference treatment
Patients randomised to the reference treatment arm are
operated on preferably within the first 7 days, depending
on anticoagulant or antithrombotic therapy use, severity
of symptoms and discretion of the treating physician.
Surgery will take place through BHC followed by insertion
of a subdural drain for 2 days in line with the standard
protocols in each participating hospital. Antibiotic
prophylaxis is administered preoperatively. Either general
or local anaesthesia will be applied. One or two 14-mm
Fig. 1 Time schedule of study procedures
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burr holes, depending on the surgeon’s discretion, are
drilled over the maximum width of the haematoma. The
dura mater is opened with a cruciate incision and coagu-
lated with bipolar diathermy. The subdural collection is
washed out with warm Ringer’s lactate saline, with or
without a catheter. The subdural outer and inner
membrane loculations, if present, can be disrupted when
easily accessible via the burr holes. Whenever the saline
has dispersed sufficiently a subdural drain is placed and
the wound is closed.
Fig. 2 Flow diagram of main study procedures
Table 4 Dexamethasone (DXM) dosing scheme
Day DXM dosage
1–4 8 mg every 12 h
5–7 4 mg every 12 h
8–10 2 mg every 12 h
11–13 1 mg every 12 h
14–16 0.5 mg every 12 h
17–19 0.5 mg per day
20 Stop
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Reoperation can be indicated when neurological
deficits do not resolve, deteriorate or recur within the
follow-up duration. Treatment options consist of redo
burr-hole evacuation, if necessary, through another
additional hole, percutaneous aspiration, craniotomy, or
craniectomy.
Concomitant care
All included patients will otherwise receive routine
standard of care. Patients with mild neurological deficits
(MGS grade 1) on admission can be discharged home in
anticipation of the planned BHC or awaiting the effect
of DXM therapy. However, in MGS grade 1 patients with
known diabetes mellitus (DM) with HbA1C< 64 mmol/
mol randomised for DXM therapy, monitoring for blood
glucose levels is necessary during the first 3 days after
treatment initiation. Glucose monitoring can take place
clinically during admission or if possible at the nursing
home. Patients with MGS grade 2–3 (in either arm) re-
main in hospital until the treating physician judges the
clinical situation safe for discharge.
During admission neurological investigations and vital
parameters are recorded daily. Low-molecular-weight
heparin (LMWH) will be applied in both patient groups
as thrombosis prophylaxis if the patient is not optimally
mobile. Patients will receive physiotherapy, speech the-
rapy or rehabilitation consultation if deemed necessary.
Anticoagulant or antithrombotic therapy Oral anti-
coagulant or antithrombotic therapy will be discontinued in
both study arms from the moment of randomisation to
prevent haematoma growth and to avoid interference with
planned surgery. In case of vitamin K antagonist (VKA)
therapy the international normalised ratio (INR) is cor-
rected to ≤ 1.5 through the administration of vitamin K
and/or prothrombin complex concentrate (PCC), as is the
current practice. For patients using platelet-aggregation-in-
hibitor therapy, surgery is preferably planned 7 days after
discontinuation of therapy, if allowed by the clinical condi-
tion. At the discretion of the surgeon, earlier intervention is
allowed if deemed clinically necessary. The reason for early
surgery has to be recorded in the case report form (CRF).
Non-vitamin-K oral anticoagulants (NOACs) are discon-
tinued at least 1 day prior to surgery.
Any anticoagulant or antithrombotic therapy can be
resumed 2 weeks after the initiation of DXM therapy or
surgery following a follow-up CT without signs of CSDH
recurrence, recent-onset haematoma or unchanged mass
effect with midline shift compared to the initial CT at
randomisation. Partial resolution of CSDH at this stage
without recent haematoma is not a contraindication for
resumption. For absolute indications (e.g. mechanic car-
diac valve) earlier resumption or bridging of therapy
within these 14 days is allowed. Any reason for early
resumption has to be recorded in the CRF. Subgroup
analyses will be performed to evaluate the effect of anti-
coagulant therapy in both groups.
Outcomes
Primary outcome measures
The primary endpoints are the functional outcome,
expressed by mRS, at 3 months after start of study treat-
ment and cost-effectiveness at 12 months.
Secondary outcome measures
Secondary outcomes include: functional and clinical out-
come, expressed by mRS and MGS scores, respectively, at
discharge, at 2 weeks, at 3, 6 and 12 months after start of
study treatment. We will also determine a utility-weighted
mRS (UW-mRS) at 3 months. The GOSE score will be
assessed at 3 months, quality of life (expressed by SF-36
and QOLIBRI) at 3 and 12 months, cost-effectiveness at 3
and 12 months and haematoma thickness at 2 weeks.
During the first 12 months, we will evaluate haematoma
recurrence (defined as recurrence of symptoms and
neurological signs after initial improvement with persis-
tence, recurrence or increase of CSDH on follow-up CT),
failure of therapy after randomisation and requiring inter-
vention, complications and drug-related adverse events,
duration of hospital stay and healthcare and productivity
costs in both patient groups. Finally, we will evaluate
mortality during the first 3 and 12 months.
Randomisation
Patients are randomised in a 1:1 allocation ratio stratified
for study site by their treating physician. Stratified
block-randomisation is done by using a computer rando-
misation algorithm to generate balanced random samples
(Castor EDC, Ciwit B.V., Amsterdam, The Netherlands).
Sample size
This RCT is designed as a non-inferiority study. The
sample size for showing non-inferiority is calculated
based on a simulation programme in R statistical soft-
ware for power for ordinal regression. We aim to include
420 patients. This sample size yields a power of 90%,
assuming that the true effect of DXM is an odds ratio
1.15 for a better functional outcome on the mRS, and
the limit for inferiority is an odds ratio < 0.9.
Data collection
All patient data is collected in the electronic data cap-
ture software Castor EDC (Ciwit B.V., Amsterdam, The
Netherlands). This software allows built-in logical checks
and validations to promote data quality. Data entry is
performed locally by trained research nurses and physi-
cians. No patient-identifying information is collected.
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Data analysis
The primary effect parameter (and all other comparisons
of the treatment arms) will be performed on all rando-
mised subjects according to the intention-to-treat (ITT)
principle. A sensitivity analysis is performed for the pri-
mary outcome measure in a per-protocol fashion, defined
as patients in the ITT population receiving treatment as
randomised without protocol violation.
The primary effect parameter will be the adjusted com-
mon odds ratio (acOR) for a shift in the direction of a bet-
ter outcome on the mRS at 3 months with 95% confidence
interval, estimated with multivariable ordinal logistic re-
gression with adjustment for important prognostic baseline
variables. This analysis is becoming the standard for or-
dinal functional outcomes in neurology and neurosurgery,
supported by evidence for its maximisation of statistical
power while maintaining interpretability. Missing data in
baseline characteristics will be imputed using multiple im-
putation (n = 10) based on the outcome and relevant base-
line covariates using the ‘Multivariate Imputation by
Chained Equations’ (MICE) algorithm. Patients with miss-
ing primary outcome will be excluded but every effort will
be made to obtain follow-up. To accept the null hypothesis
(H0) of non-inferiority the lower 95% confidence limit of
the odds ratio for a better functional outcome on the mRS
of DXM versus surgery should be equal to or above 0.9.
Furthermore, we will perform an extensive economic
evaluation of DXM versus surgery for patients with a
CSDH. The economic evaluation will be performed accord-
ing to the Dutch guidelines, using a societal perspective.
The timeframe will be 12 months to take all relevant costs
and effects into account. The primary effect measure for
the economic evaluation will be functional status (mRS).
Secondary outcome measures for the cost-effectiveness
analyses (CEA) will be mortality and quality-adjusted life
year (QALY), based on the 12-month SF-36 and QOLIBRI
summary scores. The cost-effectiveness will be assessed by
calculating the incremental cost-effectiveness ratio (ICER),
defined as the difference in costs, divided by the average
change in effectiveness of DXM versus surgery in CSDH
patients. The cost-effectiveness analysis will use the mRS as
effect measure and the cost-utility analysis will use the
QALY as effect measure.
Uncertainty around this ratio will be presented using
confidence eclipses on the cost-effectiveness plane and
acceptability curves. We will perform a sensitivity analysis
to assess the robustness of the results to changes in costs
and effectiveness parameters. Due to the short time hori-
zon, no discounting for costs and effects will be used (see
Additional file 2 for statistical analysis plan).
For secondary endpoint parameters, Kaplan-Meier and
Cox regression analysis will be used for mortality
comparisons between the treatment arms, binary logistic
regression for complications and failure of therapy, and
a linear regression to evaluate quality of life. A p value
of less than 0.05 will be used to indicate statistical




The coordinating investigator will visit study centres
every 3 months to discuss any issues and check on con-
duct of the study. Prior to recruitment, the field team
(physicians) will receive information and instructions on
the objectives of the study, methods and processes of the
study. CRF data will be monitored by an independent
external expert at regular intervals throughout the study
to verify adherence to the protocol and data complete-
ness, consistency and accuracy.
Data Safety Monitoring Board (DSMB)
In order to increase the safety of the intervention the
trial will be monitored by an independent Data Safety
Monitoring Board (DSMB). The DSMB will work in
accordance with a dedicated charter and will follow pro-
cesses recommended by the DAMOCLES Statement.
The DSMB will be chaired by a neurosurgeon, and in-
clude a neurologist and an independent methodologist/
statistician. The DSMB will meet at least annually or
after inclusion of the next 150 patients (whichever
comes first). With respect to study safety and efficacy,
interim analyses of major endpoints (including serious
adverse events believed to be due to treatment) are per-
formed after 150 and 300 patients have completed their
follow-up evaluation. In addition, the DSMB will review
the study logistics/trial conduct in terms of: assessment
of compliance with the study protocol (including adhe-
rence to inclusion and exclusion criteria) and monitor
data quality (completeness), time to start of the proce-
dure (DXM/surgery), cross-overs, occurrence and list-
ing/registration of (serious) adverse events, by centre
and by treatment arm.
Adverse events (AEs) and serious adverse events (SAEs)
Adverse events are defined as any undesirable event
occurring to a patient during the study, whether or not
considered related to DXM therapy or surgery. All
adverse events reported spontaneously by the patient or
observed by the investigator or staff will be recorded. A
SAE is any untoward medical occurrence or effect that
results in death; is life-threatening (at the time of the
event); requires hospitalisation or prolongation of exis-
ting inpatients’ hospitalisation; results in persistent or
significant disability or incapacity or any other important
medical event that did not result in any of the outcomes
listed above due to medical or surgical intervention, but
could have been based upon appropriate judgement by
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the investigator. SAEs are reported by the investigators
in participating centres to the coordinating investigator.
SAEs will be reported through the web portal Toetsin-
gOnline to the accredited Medical Ethics Committee that
approved the protocol.
Interim analysis
Interim analyses of major endpoints (including serious
adverse events believed to be due to treatment) are per-
formed after 150 and 300 patients have completed their
follow-up evaluation.
Dissemination of results
Trial results will be published in an international jour-
nal, communicated to neurological and neurosurgical as-
sociations and presented at (inter)national congresses.
Discussion
General guidelines defining the preferred treatment for
CSDH are lacking, but worldwide, surgery is the current
standard practice. Various hospitals, however, apply
DXM as an alternative treatment modality or as an ad-
junctive therapy prior to surgery. To date, no
head-to-head trial comparing the two modalities in a
well-defined cohort of patients has been performed to
our knowledge. The competing benefit of either treat-
ment is, therefore, not clear.
CSDH development occurs likely due to (mild) trau-
matic brain injury causing a tear in the dural border cell
layer which leads to extravasation of cerebrospinal fluid
and blood in the subdural space. At a point neurological
deficits arise because of a mass effect due to liquefaction
and progressive enlargement of an initially small haema-
toma. The rationale behind corticosteroid therapy is
based on results of previous experimental work that
postulates an inflammatory response to be responsible
for the haematoma enlargement [13, 14, 18–23]. Accu-
mulated blood in the subdural space, in particular
erythrocyte breakdown products, incites an inflamma-
tory reaction that results in the deposition of fibrin and
formation of subdural neo-membranes with in-growth of
neo-capillaries. These neo-membranes are vulnerable
structures with high vascularisation of the outer layer
and are prone to rupture and bleed. Furthermore, it is
also believed that the outer layer of the neo-membrane
contains a high content of plasminogen and plasmino-
gen activator, which cause an enzymatic fibrinolysis and
liquefaction of the initial blood clot in the inner haema-
toma. This situation finally results in frequent effusions
of plasma or rebleeding from the neo-membranes into
the subdural collection. Hence, a cascade of inflamma-
tion, impaired coagulation, angiogenesis and fibrinolysis
plays an important role in the formation of CSDH.
Despite this dynamic hypothesis regarding the patho-
physiology of CSDH, high-quality data supporting the use
of DXM therapy as alternative treatment to surgery is
scarce. Previous studies have shown favourable results of
DXM as adjunctive to surgery in reducing mortality [24]
and reoperation rate [15, 25, 26]. In current literature only
four (non-randomised) studies evaluated the effect of
corticosteroids in CSDH management as monotherapy
compared to corticosteroids as an adjunctive to surgery or
surgery alone [15]. In each study a different primary
outcome measure was applied, of which only two used a
validated outcome scale to assess functional outcome.
Of these two studies, the first study had a prospective de-
sign and evaluated 112 patients in four patient groups:
DXM monotherapy, DXM in combination with surgery by
BHC without additional drainage, surgery only and obser-
vation only [27]. This study revealed a favourable outcome,
defined by a Glasgow Outcome Scale (GOS) score of 4–5
at 6 months, in 88% after DXM monotherapy. The reported
success rate (GOS 4–5) for DXM therapy adjunctive to
surgery was 91%, compared to 77% after surgery alone and
50% after observation only. The second study described a
retrospective evaluation in 122 patients in slightly different
patient groups: initial DXM therapy, surgery alone by
twist-drill mini-craniostomy, surgery alone by craniotomy
and observation only [28]. A favourable outcome was
expressed by a Markwalder Grading Scale (MGS) score of
0–2 at discharge and was achieved in 73% after DXM
monotherapy. In 25% of patients receiving initial DXM
therapy, monotherapy failed and additional surgery was
required in this group. In the primary surgical groups the
reported success rates (MGS score 0–2) were 93 and 75%
after twist-drill mini-craniostomy and craniotomy, respec-
tively, and for the observation only group 100%.
In contrast, extensive research has been performed
regarding the several operative techniques. Different sur-
gical techniques can be applied, such as craniotomy,
BHC or twist-drill craniostomy, with or without place-
ment of a subdural drain. To date, no class I evidence
exists to compare the various methods of haematoma
evacuation. A recent large systematic review evaluated all
24 available RCTs regarding surgical treatment of CSDH.
The only significant finding was a reduction in haema-
toma recurrence after postoperative subdural drainage
based on eight RCTs [9]. In addition, one of the largest
RCTs, performed in 215 symptomatic CSDH patients,
showed that subdural drainage compared to no drainage
not only lowered recurrence rate, but also reduced morta-
lity and improved functional outcome at 6 months [10].
Overall, surgical techniques have been thoroughly
demonstrated as effective therapy in the current litera-
ture for CSDH patients. DXM is showing promising
results as an alternative treatment, but confirmation of
these results is essential by means of RCTs.
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Trial status
This trial started on 1 September, 2016. The first patient
was included in Medical Centre Haaglanden (HMC) The
Hague and subsequently enrolment was started in Haga
Teaching Hospital The Hague and Leiden University
Medical Centre (LUMC) Leiden. The trial will start on 1
August 2018 at Erasmus Medical Centre (EMC) and
Medisch Spectrum Twente (MST) and on 1 September
2018 at Isala Hospital Zwolle and Groningen University
Medical Centre (UMCG). The study is open to
additional participating neurosurgical centres.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist. (PDF 181 kb)
Additional file 2: Statistical analysis plan. (PDF 253 kb)
Abbreviations
BHC: Burr-hole craniostomy; CEA: Cost-effectiveness analyses; CSDH: Chronic
subdural haematoma; CT: Computed tomography; DM: Diabetes mellitus;
DSMB: Data Safety Monitoring Board; DXM: Dexamethasone; EMC: Erasmus
University Medical Centre; GOS: Glasgow Outcome Scale; GOSE: Glasgow
Outcome Scale-Extended; HMC: Haaglanden Medical Centre;
INR: International normalised ratio; LUMC: Leiden University Medical Centre;
METC: Medical Ethics Committee; MGS: Markwalder Grading Scale;
MRS: Modified Rankin Scale; MST: Medisch Spectrum Twente; NOAC: New
oral anticoagulant; OD: Once a day; PCC: Prothrombin complex concentrate;
QOLIBRI: Quality of Life in Brain Injury; RCT: Randomised controlled trial;
SF-36: Short Form – 36 Health Survey; UMCG: University Medical Centre
Groningen; VKA: Vitamin K antagonist; ZonMw: Netherlands Organisation for
Health Research and Development
Acknowledgements
We want to thank R. Wolterbeek and Ewout Steyerberg (Department of
Medical Statistics, Leiden University Medical Centre) and Suzanne Polinder
(Department of Public Health Erasmus MC) for their support with the study
design and analyses of the RCT and CEA. We also want to thank the local
investigators for their effort in conducting the study in the participating
centres.
Funding
Funding was received from Jacobus Stichting The Hague, the Research
Bureau (Landsteiner Instituut) of the Haaglanden Medical Centre (HMC),
ZonMw (Netherlands Organisation for Health Research and Development)
grant (project number 843002824, 2017; EMC and MST) and the Erasmus MC
(Mrace, project number 2016-16118; EMC). In a joined effort these are com-
bined in the DECSA trial and the Dutch Subdural Haematoma Research
Group was founded.
Availability of data and materials
The dataset generalised and analysed during the current study is available
from the corresponding author on reasonable request.
Protocol version
This manuscript is based on the most recent protocol version, version 6 April
2018.
Authors’ contributions
IPM designed the study, obtained funding, wrote the study protocol, is
responsible for the implementation and organisation of the study in all
participating centres, the conduct of the database and will perform the
statistical analyses. WCP designed the study and is responsible for the local
conduct of the study at LUMC. NAG designed the study and is responsible
for the local conduct of the study at Haga Teaching Hospital. KJ designed
the study and is responsible for the local conduct of the study at HMC. RD
designed the study and is responsible for the local conduct of the study at
EMC. HFL designed the study, obtained funding and is responsible for the
statistical analyses and statistical analyses plan. VV contributed to the design
of the study. HMH designed the study and is responsible for the local
conduct of the study at Isala Hospital. DCH wrote the study protocol and is,
together with IPM, also responsible for the implementation and organisation
of the study in all participating centres, the conduct of the database and will
perform the statistical analyses. CMFD contributed to the design of the
study. FK contributed to the design of the study. KHK contributed to the
design of the study and is responsible for the local conduct of the study at
MST. RW contributed to the design of the study and is, together with KJ,
responsible for the local conduct of the study at HMC. NK contributed to the
design of the study and is, together with WCP, responsible for the local
conduct of the study at LUMC. RK contributed to the design of the study
and is, together with WCP and NK, responsible for the local conduct of the
study at LUMC. KL contributed to the design of the study and is, together
with NAG, responsible for the local conduct of the study at Haga Teaching
Hospital. JN contributed to the design of the study and is responsible for the
local conduct of the study at UMCG. RJMG contributed to the design of the
study and is, together with JN, responsible for the local conduct of the study
at UMCG. BJ contributed to the design of the study and is, together with JN
and RJMG, responsible for the local conduct of the study at UMCG. All
authors read and approved the final version of the manuscript.
Ethics approval and consent to participate
The study received approval by the Medical Ethics Committee (METC Zuid
West Holland). This trial has been registered in the European Union Clinical
Trials Register (EUCTR) and is conducted in compliance with the European
Union Clinical Trials Directive (2001/20/EC) and the principles of the
Declaration of Helsinki (2013).
For eligible patients, written informed has to be obtained by their treating
physician. If a patient is not capable to give written informed consent (i.e.
due to altered consciousness or aphasia), the treating physician will ask the
legal representative to provide written informed consent. Once the patient is
capable of giving their own informed consent, the treating physician (at the
ward or outpatient clinic) will ask the patient to provide written informed
consent. If the patient withdraws their permission, the patient data will not
be used for this study.
Consent for publication
By giving written informed consent, patients agree with the storage of data
and publication of the study results.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Neurology and Neurosurgery, Haaglanden Medical Centre
(HMC), Lijnbaan 32, 2512 VA The Hague, The Netherlands. 2Department of
Neurology and Neurosurgery, Erasmus Medical Centre (EMC), Dr.
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. 3Department of
Public Health, Erasmus Medical Centre (EMC), Dr. Molewaterplein 40, 3015
GD Rotterdam, The Netherlands. 4Department of Neurology and
Neurosurgery, Leiden University Medical Centre (LUMC), Albinusdreef 2, 2333
ZA Leiden, The Netherlands. 5Department of Neurology and Neurosurgery,
Haga Teaching Hospital, Els Borst-Eilersplein 275, 2545 AA The Hague, The
Netherlands. 6Department of Neurosurgery, Medisch Spectrum Twente (MST),
Koningsplein 1, 7512 KZ Enschede, The Netherlands. 7Department of
Neurology, Isala Hospital Zwolle, Dokter van Heesweg 2, 8025 AB Zwolle, The
Netherlands. 8Department of Neurology and Neurosurgery, University of
Groningen, University Medical Centre Groningen (UMCG), Hanzeplein 1, 9713
GZ Groningen, The Netherlands.
Miah et al. Trials          (2018) 19:575 Page 9 of 10
Received: 30 December 2017 Accepted: 26 September 2018
References
1. Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B,
Yarascavitch B, et al. Chronic subdural haematoma management: a
systematic review and meta-analysis of 34829 patients. Ann Surg. 2014;259:
449–57.
2. Stichting Farmaceutische Kengetallen. Meer geneesmiddelen bij trombose.
Pharmaceutisch Weekblad. 2008;143:41.
3. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, DeRosa PL, Andersen
KN, et al. The surgical management of chronic subdural haematoma.
Neurosurg Rev. 2012;35:155–69.
4. Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and
anticoagulation or anti-thrombotic therapy. J Clin Neurosci. 2006;13:823–7.
5. Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural haematoma
in the elderly: not a benign disease. J Neurosurg. 2011;114:72–6.
6. Asghar M, Adhiyaman V, Greenway MW, Bhowmick BK, Bates A. Chronic
subdural haematoma in the elderly—a North Wales experience. J R Soc
Med. 2002;95:290–2.
7. Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N. Chronic subdural
haematoma in elderly people: present status on Awaji Island and
epidemiological prospect. Neurol Med Chir. 1992;32:207–9.
8. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural
haematoma: modern management and emerging therapies. Nat Rev
Neurol. 2014;10:570–8.
9. Ivamoto HS, Lemos HP, Atallah AN. Surgical treatments for chronic subdural
haematomas: a comprehensive systematic review. World Neurosurg. 2016;
86:399–418.
10. Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P,
et al. Use of drains versus no drains after burr-hole evacuation of
chronic subdural haematoma: a randomised controlled trial. Lancet.
2009;374:1067–73.
11. Liu W, Bakker NA, Groen RJM. Chronic subdural haematoma: a systematic
review and meta-analysis of surgical procedures. J Neurosurg. 2014;121:665–73.
12. Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for
chronic subdural haematoma: evidence based review. J Neurol Neurosurg
Psychiatry. 2003;74:937–43.
13. Drapkin AJ. Chronic subdural haematoma: pathophysiological basis for
treatment. Br J Neurosurg. 1991;5:467–73.
14. Holl DC, Volovici V, Dirven CMF, Peul WC, Jellema K, van der Gaag NA, et al.
Pathophysiology and targets for non-surgical therapy of chronic
subdural haematoma: evolution from past to present to future. World
Neurosurg. 2018;116:402–11.
15. Berhauser Pont LME, Dirven CMF, Dippel DWJ, Verweij BH, Dammers R. The
role of corticosteroids in the management of chronic subdural haematoma:
a systematic review. Eur J Neurol. 2012;19:1397–403.
16. Berkhemer OA, Fransen PSS, Beumer D, Van den Berg LA, Lingsma HF, Yoo
AJ, et al. A randomized trial of intraarterial treatment for acute ischemic
stroke. N Engl J Med. 2015;372:11–20.
17. Markwalder T, Steinsiepe KF, Rohner M, Reichenbach W, Markwalder H. The
course of chronic subdural haematomas after burr-hole craniostomy and
closed-system drainage. J Neurosurg. 1981;55:390–6.
18. Ito H, Yamamoto S, Komai T, Mizukoshi H. Role of local hyperfibrinolysis in
the etiology of chronic subdural haematoma. J Neurosurg. 1976;45:26–31.
19. Ito H, Komai T, Yamamoto S. Fibrinolytic enzyme in the lining walls of
chronic subdural haematoma. J Neurosurg. 1978;48:197–200.
20. Labadie EL, Glover D. Local alterations of hemostatic-fibrinolytic
mechanisms in reforming subdural haematomas. Neurology.
1975;25:669–75.
21. Labadie EL, Glover D. Physiopathogenesis of subdural haematomas: part II:
inhibition of growth of experimental haematomas with dexamethasone.
J Neurosurg. 1976;45:393–7.
22. Trappe A, Hafter R, Wendt P, Graeff H, Blümel G. Detection of fibrinolysis in
chronic subdural haematoma. Neurochirurgia. 1986;29:78–82.
23. Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ.
Pathophysiology of chronic subdural haematoma: inflammation,
angiogenesis and implications for pharmacotherapy. J Neuroinflammation.
2017;159:2037–44.
24. Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P. Efficacité de la
corticothérapie dans le traitement adjuvant des hématomes sous-duraux
chroniques. Étude rétrospective sur 198 cas. Neurochirurgie. 2007;53:477–82.
25. Chan DYC, Sun TFD, Poon WS. Steroid for chronic subdural haematoma?
A prospective phase IIB pilot randomized controlled trial on the use of
dexamethasone with surgical drainage for the reduction of recurrence with
surgical drainage for the reduction of recurrence with operation. Chin
Neurosurg J. 2015.
26. Qian Z, Yang D, Sun F, Sun Z. Risk factors for recurrence of chronic subdural
haematoma after burr hole surgery: potential protective role of
dexamethasone. Br J Neurosurg. 2017;31:84–8.
27. Sun TF, Boet R, Poon WS. Non-surgical primary treatment of chronic
subdural haematoma: preliminary results of using dexamethasone. Br J
Neurosurg. 2005;19:327–33.
28. Delgado-Lopez PD, Martin-Velasco V, Castilla-Diez JM, Rodriquez-Salazar A,
Galacho-Harriero AM, Fernandex-Arconada O. Dexamethasone treatment in
chronic subdural haematoma. Neurocirugia (Astur). 2009;20:346–59.
Miah et al. Trials          (2018) 19:575 Page 10 of 10
